The global gene transfer technologies market, valued at US$3.63 billion in 2023, is forecasted to grow at a robust CAGR of 9.7%, reaching US$3.73 ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 ...

Another exciting area of personalized medicine is using nanotechnology for gene therapy. Gene therapy involves altering or ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Detailed price information for Immunoprecise Antibodies Ltd (IPA-Q) from The Globe and Mail including charting and trades.

An interview on how advanced techniques can be used to enhance silk fibroin and chitosan for drug delivery applications.

Gene Quinn is a patent attorney and a leading commentator on patent law and innovation policy. Mr. Quinn has twice been named one of the top 50 most influential people in IP by Managing IP ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...